AU2005269733B2 - Induction of apoptosis in Toll-like receptor expressing tumor cells - Google Patents

Induction of apoptosis in Toll-like receptor expressing tumor cells Download PDF

Info

Publication number
AU2005269733B2
AU2005269733B2 AU2005269733A AU2005269733A AU2005269733B2 AU 2005269733 B2 AU2005269733 B2 AU 2005269733B2 AU 2005269733 A AU2005269733 A AU 2005269733A AU 2005269733 A AU2005269733 A AU 2005269733A AU 2005269733 B2 AU2005269733 B2 AU 2005269733B2
Authority
AU
Australia
Prior art keywords
cells
cell
poly
tlr
tlr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005269733A
Other languages
English (en)
Other versions
AU2005269733A1 (en
Inventor
Isabelle Coste-Invernizzi
Serge Lebecque
Toufic Renno
Marie-Clotilde Rissoan
Bruno Salaun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2005269733A1 publication Critical patent/AU2005269733A1/en
Application granted granted Critical
Publication of AU2005269733B2 publication Critical patent/AU2005269733B2/en
Priority to AU2008249173A priority Critical patent/AU2008249173A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005269733A 2004-07-20 2005-07-19 Induction of apoptosis in Toll-like receptor expressing tumor cells Ceased AU2005269733B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008249173A AU2008249173A1 (en) 2004-07-20 2008-11-24 Induction of apoptosis in toll-like receptor expressing tumor cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58961604P 2004-07-20 2004-07-20
US60/589,616 2004-07-20
PCT/US2005/025602 WO2006014653A1 (en) 2004-07-20 2005-07-19 Induction of apoptosis in toll-like receptor expressing tumor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008249173A Division AU2008249173A1 (en) 2004-07-20 2008-11-24 Induction of apoptosis in toll-like receptor expressing tumor cells

Publications (2)

Publication Number Publication Date
AU2005269733A1 AU2005269733A1 (en) 2006-02-09
AU2005269733B2 true AU2005269733B2 (en) 2008-10-30

Family

ID=35229744

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005269733A Ceased AU2005269733B2 (en) 2004-07-20 2005-07-19 Induction of apoptosis in Toll-like receptor expressing tumor cells
AU2008249173A Abandoned AU2008249173A1 (en) 2004-07-20 2008-11-24 Induction of apoptosis in toll-like receptor expressing tumor cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008249173A Abandoned AU2008249173A1 (en) 2004-07-20 2008-11-24 Induction of apoptosis in toll-like receptor expressing tumor cells

Country Status (12)

Country Link
US (2) US20060147456A1 (enExample)
EP (1) EP1768699A1 (enExample)
JP (1) JP2008507530A (enExample)
KR (1) KR20070043795A (enExample)
CN (1) CN101018567B (enExample)
AT (1) ATE511859T1 (enExample)
AU (2) AU2005269733B2 (enExample)
CA (1) CA2574176A1 (enExample)
MX (1) MX2007000770A (enExample)
NO (1) NO20070945L (enExample)
RU (1) RU2401661C9 (enExample)
WO (1) WO2006014653A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
AU2004225480A1 (en) * 2003-03-26 2004-10-14 Multicell Immunotherapeutics, Inc. Selected RNA motifs to include cell death and/or apoptosis
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20120189643A1 (en) * 2004-11-30 2012-07-26 Carton Jill M Toll Like Receptor 3 Antagonists, Methods and Uses
EP2522352B1 (en) 2006-03-02 2017-01-11 Agency for Science, Technology and Research Methods for stem cells modulation
US8957035B2 (en) 2006-05-15 2015-02-17 University Of Kentucky Research Foundation Toll like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
JP5115921B2 (ja) * 2007-02-28 2013-01-09 株式会社ペルセウスプロテオミクス 腎癌の診断薬および治療薬
AU2008242540A1 (en) * 2007-04-24 2008-10-30 John Wayne Cancer Institute Functional toll-like receptors (TLR) on melanocytes and melanoma cells and uses thereof
SG185942A1 (en) * 2007-11-02 2012-12-28 Agency Science Tech & Res Methods and compounds for preventing and treating a tumour
JP2011505011A (ja) * 2007-11-28 2011-02-17 スマート チューブ，インコーポレイテッド 生体試料の採取、刺激、安定化及び分析のためのデバイス、システム及び方法
AU2009215795A1 (en) 2008-02-21 2009-08-27 University Of Kentucky Research Foundation Ultra-small RNAs as toll-like receptor-3 antagonists
CA2722589A1 (en) 2008-04-25 2009-10-29 Innate Pharma Improved tlr3 agonist compositions
WO2010020590A1 (en) * 2008-08-20 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators
WO2010068680A1 (en) 2008-12-10 2010-06-17 Mount Sinai School Of Medicine Of New York University Thelper cell type 17 lineage-specific adjuvants, compositions and methods
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
WO2011072871A1 (en) * 2009-12-18 2011-06-23 Bavarian Nordic A/S Production of ifn-lambda by conventional dendritic cells and uses thereof
KR101250419B1 (ko) * 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제
RU2014103159A (ru) * 2011-07-22 2015-08-27 Павел КАЛИНСКИЙ Опухолесективная модуляция хемокинов
CN102652802A (zh) * 2012-04-18 2012-09-05 南京中医药大学 癌毒方在制备调控肝癌细胞TLRs／NF-κB信号转导药物中的应用
WO2014022287A1 (en) * 2012-07-29 2014-02-06 The Regents Of The University Of Colorado, A Body Corporate Antagonists of the toll-like receptor 1/2 complex
WO2015127002A1 (en) * 2014-02-19 2015-08-27 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN105796594A (zh) * 2016-03-28 2016-07-27 南京大学 一种组合物在制备治疗肿瘤药物中的应用及该组合物的使用方法
CN106191238B (zh) * 2016-07-08 2020-01-10 中国医学科学院基础医学研究所 Tlr3预测肿瘤转移、评估预后和选择防治方案的应用
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN108295060A (zh) * 2018-04-08 2018-07-20 王长国 一种tlr7激动剂在增强cik细胞对肿瘤细胞杀伤力方面的应用
WO2020232226A1 (en) 2019-05-16 2020-11-19 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN111117966A (zh) * 2020-03-02 2020-05-08 南通大学 一种利用乳酸的体外细胞培养方法
CN111579538B (zh) * 2020-04-22 2022-12-30 山东第一医科大学(山东省医学科学院) 一种利用凋亡试剂盒检测循环肿瘤细胞的方法
CA3221194A1 (en) * 2021-05-24 2022-12-01 Cha Vaccine Research Institute Co., Ltd Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047612A2 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
WO2004050868A1 (ja) * 2002-11-29 2004-06-17 Japan Science And Technology Agency 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CN1040504A (zh) * 1988-06-22 1990-03-21 Hem研究公司 用双链核糖核酸调节淋巴激活素抗性细胞状态
RU2136278C1 (ru) * 1998-04-07 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Противоопухолевое средство
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AU2002360243A1 (en) * 2001-07-26 2003-05-06 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047612A2 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
WO2004050868A1 (ja) * 2002-11-29 2004-06-17 Japan Science And Technology Agency 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDRE, F et al. JOURNAL OF CLINICAL ONCOLOGY. Vol 22. No 4.,2004. pg 9619 *

Also Published As

Publication number Publication date
WO2006014653A1 (en) 2006-02-09
NO20070945L (no) 2007-02-19
CN101018567A (zh) 2007-08-15
CN101018567B (zh) 2011-07-27
RU2401661C2 (ru) 2010-10-20
KR20070043795A (ko) 2007-04-25
AU2008249173A1 (en) 2008-12-11
US20060147456A1 (en) 2006-07-06
US20090285779A1 (en) 2009-11-19
AU2005269733A1 (en) 2006-02-09
JP2008507530A (ja) 2008-03-13
RU2007105987A (ru) 2008-08-27
EP1768699A1 (en) 2007-04-04
CA2574176A1 (en) 2006-02-09
ATE511859T1 (de) 2011-06-15
MX2007000770A (es) 2007-03-26
RU2401661C9 (ru) 2011-01-27

Similar Documents

Publication Publication Date Title
AU2005269733B2 (en) Induction of apoptosis in Toll-like receptor expressing tumor cells
US20240043541A1 (en) Methods for treating hematologic cancers
Beider et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth
US20210179687A1 (en) Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
US11081235B2 (en) Extracellular matrix metalloproteinase inducer (EMMPRIN) peptides and binding antibodies
Leiguarda et al. IMT504 provides analgesia by modulating cell infiltrate and inflammatory milieu in a chronic pain model
WO2011113041A2 (en) Neutralization of flt3 ligand as a leukemia therapy
US20160209425A1 (en) Use of dectin-1 activators for treatment of liver disorders
WO2022265864A2 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
US10231952B2 (en) Use of arginine vasopressin receptor antagonists for the treatment of prostate cancer
JP5665739B2 (ja) 炎症性疾患を治療するためのｃｄ９５インヒビターの使用
JP5695905B2 (ja) Ｎｌｒｒ−１アンタゴニスト及びその使用
Wang et al. Tumor-responsive, multifunctional CAR-NK cells cooperate with impaired autophagy to infiltrate and target glioblastoma
KR101781257B1 (ko) Rip3 발현촉진제를 유효성분으로 포함하는 항암보조용 조성물
US20210100859A1 (en) Herpes simplex virus (hsv) anticancer therapies
JP2010540653A5 (enExample)
US20240391964A1 (en) Compositions and methods for the treatment of cancer
US20220290151A1 (en) Use of müllerian inhibiting substance inhibitors for treating cancer
Dalton et al. Bone Marrow Stroma Confers Resistance to

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired